{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:36:59Z","timestamp":1783003019632,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study was to investigate the expression and clinical implications of CCN family member 5 (CCN5) and the oestrogen receptor (ER) in advanced breast cancer (BC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 130 patients with advanced BC were selected for the study. Samples of normal breast tissue, ductal carcinoma in situ (DCIS), and invasive carcinoma were collected. The expression levels of CCN5 and ER in these tissues were examined using immunohistochemical methods. The correlation between expression of CCN5 and ER in different tissues and also differences in expression in invasive carcinoma were analysed. In addition, the relationship between CCN5 expression in advanced BC tissues and clinical pathological features was examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CCN5 and ER had low expression in normal breast tissues and invasive carcinoma tissues, but high expression in DCIS, with this difference being statistically significant (X\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u2009119.899,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001; X\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u2009113.524,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively). The expression of CCN5 and ER in different tissues of patients with advanced BC showed a positive correlation. Significant differences were also observed in the positive and negative expression of CCN5 and ER (X\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200956.358,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Moreover, the expression of CCN5 protein in advanced BC showed a statistically significant associations (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) with the expression of the progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), Ki-67, and P53, tumor diameter, histological grade, lymph node metastasis, pathological molecular subtype, and clinical staging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High expression of CCN5 and ER was observed in DCIS tissues of patients with advanced BC, with their expression being positively correlated. These findings suggest that CCN5 and ER may have a potential synergistic role in the progression of BC that influences the progression of advanced BC and can also be used to predict the effectiveness of endocrine therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-025-03608-3","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T02:27:03Z","timestamp":1740623223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expression and clinical significance of CCN5 and the oestrogen receptor in advanced breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Guofeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"2","key":"3608_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","volume":"83","author":"C Katsura","year":"2022","unstructured":"Katsura C, Ogunmwonyi I, Kankam HK, et al. Breast cancer: presentation, investigation and management. Br Hosp Med (Lond). 2022;83(2):1\u20137.","journal-title":"Br Hosp Med (Lond)"},{"key":"3608_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000447549","volume":"11","author":"C Liedtke","year":"2016","unstructured":"Liedtke C, Kolberg HC. Systemic therapy of advanced\/metastatic breast cancer\u2014current evidence and future concepts. Breast Care. 2016;11:275\u201381.","journal-title":"Breast Care"},{"issue":"1","key":"3608_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22024-3","volume":"12","author":"L Garcia-Martinez","year":"2021","unstructured":"Garcia-Martinez L, Zhang Y, Nakata Y, et al. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12(1):1\u201314.","journal-title":"Nat Commun"},{"issue":"1","key":"3608_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.11-1-1","volume":"11","author":"L Giacinti","year":"2006","unstructured":"Giacinti L, Claudio PP, Lopez M, et al. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist. 2006;11(1):1\u20138.","journal-title":"Oncologist"},{"issue":"2\u20133","key":"3608_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF00666157","volume":"31","author":"R Clarke","year":"1994","unstructured":"Clarke R, Skaar T, Baumann K, et al. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat. 1994;31(2\u20133):237\u201348.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3608_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2009","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2009;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"key":"3608_CR7","doi-asserted-by":"publisher","first-page":"9308","DOI":"10.1158\/0008-5472.CAN-06-1769","volume":"66","author":"JC Harrell","year":"2006","unstructured":"Harrell JC, Dye WW, Allred DC, et al. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 2006;66:9308\u201315.","journal-title":"Cancer Res"},{"issue":"4","key":"3608_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000508675","volume":"15","author":"AD Hartkopf","year":"2020","unstructured":"Hartkopf AD, Grischke EM, Brucker SY. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care (Basel). 2020;15(4):347\u201354.","journal-title":"Breast Care (Basel)"},{"issue":"1","key":"3608_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med. 2011;62(1):233\u201347.","journal-title":"Ann Rev Med"},{"key":"3608_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/B:BREA.0000014042.54925.cc","volume":"83","author":"M Lacroix","year":"2004","unstructured":"Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 2004;83:249\u201389.","journal-title":"Breast Cancer Res Treat"},{"key":"3608_CR11","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/onc.2011.483","volume":"31","author":"F Vesuna","year":"2012","unstructured":"Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha. Oncogene. 2012;31:3223\u201334.","journal-title":"Oncogene"},{"issue":"8","key":"3608_CR12","doi-asserted-by":"publisher","first-page":"R337","DOI":"10.1530\/ERC-16-0121","volume":"23","author":"CG Murphy","year":"2016","unstructured":"Murphy CG, Dickler MN. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer. 2016;23(8):R337-352.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"3608_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087878","volume":"9","author":"N Ferrand","year":"2014","unstructured":"Ferrand N, Gnanapragasam A, Dorothee G, et al. Loss of WISP\/CCN5 in estrogen-dependent MCF7 human breast cancer cells promotes a stem like cell phenotype. PLoS ONE. 2014;9(2): e87878.","journal-title":"PLoS ONE"},{"issue":"1","key":"3608_CR14","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/s41598-017-00916-z","volume":"7","author":"A Das","year":"2017","unstructured":"Das A, Dhar K, Maity G, et al. Deficiency of CCN5\/WISP-2 driven program in breast cancer promotes cancer epithelial cells to mesenchymal stem cells and breast cancer growth. Sci Rep. 2017;7(1):1220.","journal-title":"Sci Rep"},{"issue":"33","key":"3608_CR15","first-page":"4722","volume":"45","author":"T Zhang","year":"2016","unstructured":"Zhang T, Han J. Research progress of epithelial-mesenchymal transition in breast cancer. Chongq Medic. 2016;45(33):4722\u20134.","journal-title":"Chongq Medic"},{"issue":"6","key":"3608_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/jclinpath-2012-201348","volume":"66","author":"I Roxanis","year":"2013","unstructured":"Roxanis I. Occurrence and significance of epithelial-mesenchymal transition in breast cancer. J Clin Pathol. 2013;66(6):517\u201321.","journal-title":"J Clin Pathol"},{"issue":"6","key":"3608_CR17","first-page":"1359","volume":"21","author":"SC Barreto","year":"2016","unstructured":"Barreto SC, Ray A, Ag EP. Biological characteristics of CCN proteins in tumor development. J Buon. 2016;21(6):1359\u201367.","journal-title":"J Buon"},{"key":"3608_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12079-012-0158-2","volume":"6","author":"SK Banerjee","year":"2012","unstructured":"Banerjee SK, Banerjee S. CCN5\/WISP-2: a micromanager of breast cancer progression. J Cell Commun Signal. 2012;6:63\u201371.","journal-title":"J Cell Commun Signal"},{"issue":"18","key":"3608_CR19","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.1158\/0008-5472.CAN-08-1461","volume":"68","author":"S Banerjee","year":"2008","unstructured":"Banerjee S, Dhar G, Haque I, et al. CCN5\/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res. 2008;68(18):7606\u201312.","journal-title":"Cancer Res"},{"issue":"7","key":"3608_CR20","first-page":"8433","volume":"13","author":"G Zhou","year":"2021","unstructured":"Zhou G, Gui X, Qu W. Clinical significance of CCN5 and mutant p53 in primary and recurrent lesions of breast cancer. Am J Transl Res. 2021;13(7):8433\u20137.","journal-title":"Am J Transl Res"},{"issue":"1","key":"3608_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/BJ20120311","volume":"447","author":"N Ferrand","year":"2012","unstructured":"Ferrand N, Stragier E, Redeuilh G, Sabbah M. Glucocorticoids induce CCN5\/WISP-2 expression and attenuate invasion in oestrogen receptor-negative human breast cancer cells. Biochem J. 2012;447(1):71\u20139.","journal-title":"Biochem J"},{"issue":"3","key":"3608_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1677\/joe.1.07009","volume":"191","author":"A Fritah","year":"2006","unstructured":"Fritah A, Redeuilh G, Sabbah M. Molecular cloning and characterization of the human WISP-2\/CCN5 gene promoter reveal its upregulation by oestrogens. J Endocrinol. 2006;191(3):613\u201324.","journal-title":"J Endocrinol"},{"issue":"3","key":"3608_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12079-016-0343-9","volume":"10","author":"SK Banerjee","year":"2016","unstructured":"Banerjee SK, Maity G, Haque I, Ghosh A, Sarkar S, Gupta V, Campbell DR, Von Hoff D, Banerjee S. Human pancreatic cancer progression: an anarchy among CCN-siblings. J Cell Commun Signal. 2016;10(3):207\u201316.","journal-title":"J Cell Commun Signal"},{"issue":"12","key":"3608_CR24","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1158\/0008-5472.CAN-08-0316","volume":"68","author":"G Dhar","year":"2008","unstructured":"Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5\/WISP-2. Cancer Res. 2008;68(12):4580\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"3608_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12885-018-3993-6","volume":"18","author":"I Haque","year":"2018","unstructured":"Haque I, Ghosh A, Acup S, Banerjee S, Dhar K, Ray A, Sarkar S, Kambhampati S, Banerjee SK. Leptin-induced ER-\u03b1-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK\/AKT\/STAT-pathway. BMC Cancer. 2018;18(1):99.","journal-title":"BMC Cancer"},{"issue":"1","key":"3608_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1476-5586(03)80018-0","volume":"5","author":"S Banerjee","year":"2003","unstructured":"Banerjee S, Saxena N, Sengupta K, et al. WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia. 2003;5(1):63\u201373.","journal-title":"Neoplasia"},{"key":"3608_CR27","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1128\/MCB.01335-07","volume":"3","author":"A Fritah","year":"2008","unstructured":"Fritah A, Saucier C, Wever OD, et al. Role of WISP-2\/CCN5 in maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol. 2008;3:1114\u201323.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"3608_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/bjc.2015.190","volume":"113","author":"A Talhouk","year":"2015","unstructured":"Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299\u2013310.","journal-title":"Br J Cancer"},{"issue":"3","key":"3608_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12079-016-0345-7","volume":"10","author":"CG Kleer","year":"2006","unstructured":"Kleer CG. Dual roles of CCN Proteins in breast cancer progression. J cell Commun Signal. 2006;10(3):217\u201322.","journal-title":"J cell Commun Signal"},{"issue":"6","key":"3608_CR30","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.3390\/curroncol28060417","volume":"28","author":"KA Ahmed","year":"2021","unstructured":"Ahmed KA, Hasib TA, Paul SK, et al. Potential role of CCN proteins in breast cancer: therapeutic advances and perspectives. Curr Oncol. 2021;28(6):4972\u201385.","journal-title":"Curr Oncol"},{"issue":"7","key":"3608_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1128\/MCB.01316-10","volume":"31","author":"M Sabbah","year":"2011","unstructured":"Sabbah M, Prunier C, Ferrand N, et al. CCN5, a novel transcriptional repressor of the transforming growth factor beta signaling pathway. Mol Cell Biol. 2011;31(7):1459\u201369.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"3608_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3892\/or.2013.2909","volume":"31","author":"J Ji","year":"2014","unstructured":"Ji J, Jia S, Ji K, et al. Wnt1 inducible signaling pathway protein-2(WISP-2\/CCN5):roles and regulation in human cancers(review). Oncol Rep. 2014;31(2):533\u20139.","journal-title":"Oncol Rep"},{"key":"3608_CR33","first-page":"23","volume":"2","author":"JH Fuady","year":"2014","unstructured":"Fuady JH, Bordoli MR, Abreu-Rodriguez I, Kristiansen G, Hoogewijs D, Stiehl DP, Wenger RH. Hypoxia-inducible factor-mediated induction of WISP-2 contributes to attenuated progression of breast cancer. Hypoxia. 2014;2:23\u201333.","journal-title":"Hypoxia"},{"issue":"5","key":"3608_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.43","volume":"6","author":"S Sarkar","year":"2017","unstructured":"Sarkar S, Ghosh A, Banerjee S, Maity G, Das A, Larson MA, Gupta V, Haque I, Tawfik O, Banerjee SK. CCN5\/WISP-2 restores ER- proportional, variant in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen. Oncogene. 2017;6(5): e340.","journal-title":"Oncogene"},{"issue":"1","key":"3608_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/hupa.2001.21506","volume":"32","author":"S Mann","year":"2001","unstructured":"Mann S, Laucirica R, Carlson N, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol. 2001;32(1):113\u20138.","journal-title":"Hum Pathol"},{"issue":"25","key":"3608_CR36","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","volume":"34","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guidelines. J Clin Oncol. 2016;34(25):3069\u2013103.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3608_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1158\/1541-7786.MCR-04-0130","volume":"3","author":"S Banerjee","year":"2005","unstructured":"Banerjee S, Sengupta K, Saxena NK, et al. Epidermal growth factor induces WISP-2\/CCN5 expression in estrogen receptor-{alpha}-positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res. 2005;3(3):151\u201362.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"3608_CR38","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/0008-5472.CAN-06-3753","volume":"67","author":"K Dhar","year":"2007","unstructured":"Dhar K, Banerjee S, Dhar G, et al. Insulin-like growth factor-1(IGF-1) induces WISP-2\/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells. Cancer Res. 2007;67(4):1520\u20136.","journal-title":"Cancer Res"},{"issue":"2","key":"3608_CR39","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1210\/en.2003-0823","volume":"145","author":"HR Mason","year":"2004","unstructured":"Mason HR, Grove-Strawser D, Rubin BS, et al. Estrogen induces CCN5 expression in the rat uterus in vivo. Endocrinology. 2004;145(2):976\u201382.","journal-title":"Endocrinology"},{"issue":"6","key":"3608_CR40","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1245\/s10434-007-9376-x","volume":"14","author":"SR Davies","year":"2007","unstructured":"Davies SR, Watkins G, Mansel RE, et al. Differential expression and prognostic implications of the CCN family members WISP-2, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol. 2007;14(6):1909\u201318.","journal-title":"Ann Surg Oncol"}],"updated-by":[{"DOI":"10.1186\/s12905-026-04638-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000}}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03608-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-03608-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03608-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:51:32Z","timestamp":1782971492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-025-03608-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3608"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-03608-3","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to spell error in the corresponding author name.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12905-026-04638-1","URL":"https:\/\/doi.org\/10.1186\/s12905-026-04638-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were performed in line with the principles of the Declaration of Helsinki. Approved by the Ethics Committee of The Third Hospital of Nanchang (Approval No. KY2021074). All participants were informed and they signed a fully-informed consent form. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Patient recruitment: Subject inclusion criteria and exclusion criteria were determined together with the investigator. Then, eligible subjects were actively sought by placing recruitment posters in the hospitals and communicating with doctors in relevant departments. Clinical sample processing: According to the clinical stage, clinicians have diagnosed patients with advanced breast cancer, and according to the basic information of the patients, including pathology number, hospitalization number and other relevant information, the corresponding tissue wax blocks were found for research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}